Home >> Marketplace Archives >> HTG Molecular Diagnostics and OvaGene Oncology partner, 6/14

HTG Molecular Diagnostics and OvaGene Oncology partner, 6/14

Print Friendly, PDF & Email

June 2014—HTG Molecular Diagnostics and OvaGene Oncology entered a manufacturing supply agreement in which OvaGene will design and develop its proprietary gene expression assays on HTG’s fully automated, extraction-free Edge Platform.

The Edge System uses one five-micron-thick formalin-fixed, paraffin-embedded section and is an extraction-free, automated gene expression platform that delivers multiplexed results on lysed samples in less than a day.

HTG Molecular Diagnostics, 520-547-2827


Check Also

Validation of blood test for heart transplant rejection, 12/13

December 2013—The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) and HTG Molecular Diagnostics are collaborating to begin clinical validation of a biomarker blood test that will provide early indication of organ rejection in heart transplant patients and thereby allow doctors to better monitor and treat patients post-transplant. It is the first clinical validation study of this kind in Canada.